AtheroGenics falls on AGI-1067 data

AGIX fell $4.74 (61%) to $3.09 on Monday after AGI-1067 missed the primary endpoint in the Phase III ARISE trial

Read the full 200 word article

How to gain access

Continue reading with a
two-week free trial.